Israel Englander’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21.4M | Sell |
1,193,468
-28,214
| -2% | -$534K | 0.01% | 1558 |
|
|
2026
Q1 | $26.6M | Buy |
1,221,682
+221,573
| +22% | +$4.29M | 0.01% | 1312 |
|
|
2025
Q4 | $21.5M | Buy |
1,000,109
+715,899
| +252% | +$15.1M | 0.01% | 1519 |
|
|
2025
Q3 | $5.48M | Sell |
284,210
-777,995
| -73% | -$13.9M | ﹤0.01% | 3051 |
|
|
2025
Q2 | $18.2M | Buy |
1,062,205
+855,260
| +413% | +$36.5M | 0.01% | 1675 |
|
|
2025
Q1 | $13.2M | Buy |
206,945
+193,943
| +1,492% | +$20.4M | 0.01% | 1906 |
|
|
2024
Q4 | $1.58M | Sell |
13,002
-9,078
| -41% | -$1.11M | ﹤0.01% | 3822 |
|
|
2024
Q3 | $2.76M | Sell |
22,080
-550,195
| -96% | -$76.1M | ﹤0.01% | 3397 |
|
|
2024
Q2 | $90.4M | Sell |
572,275
-301,872
| -35% | -$38.8M | 0.04% | 479 |
|
|
2024
Q1 | $113M | Buy |
874,147
+230,009
| +36% | +$28.2M | 0.05% | 398 |
|
|
2023
Q4 | $62.1M | Buy |
644,138
+294,693
| +84% | +$28.3M | 0.03% | 664 |
|
|
2023
Q3 | $42.4M | Buy |
349,445
+180,538
| +107% | +$20.4M | 0.02% | 820 |
|
|
2023
Q2 | $19.3M | Sell |
168,907
-414,017
| -71% | -$53.4M | 0.01% | 1422 |
|
|
2023
Q1 | $80.3M | Buy |
582,924
+180,933
| +45% | +$23.5M | 0.05% | 428 |
|
|
2022
Q4 | $52.1M | Sell |
401,991
-310,747
| -44% | -$36M | 0.03% | 724 |
|
|
2022
Q3 | $78.8M | Buy |
712,738
+387,072
| +119% | +$39M | 0.05% | 450 |
|
|
2022
Q2 | $24.4M | Buy |
325,666
+154,251
| +90% | +$11.3M | 0.02% | 1127 |
|
|
2022
Q1 | $13.4M | Sell |
171,415
-168,204
| -50% | -$12.9M | 0.01% | 1809 |
|
|
2021
Q4 | $30.6M | Buy |
339,619
+223,967
| +194% | +$19.1M | 0.02% | 1074 |
|
|
2021
Q3 | $10.7M | Buy |
115,652
+48,062
| +71% | +$3.7M | 0.01% | 1967 |
|
|
2021
Q2 | $5.25M | Sell |
67,590
-302,593
| -82% | -$22.9M | ﹤0.01% | 2691 |
|
|
2021
Q1 | $27.6M | Buy |
370,183
+236,994
| +178% | +$21.9M | 0.02% | 847 |
|
|
2020
Q4 | $22.7M | Buy |
133,189
+102,837
| +339% | +$15.2M | 0.02% | 970 |
|
|
2020
Q3 | $4.26K | Sell |
30,352
-94,414
| -76% | -$14.3M | 0.01% | 1984 |
|
|
2020
Q2 | $20M | Sell |
124,766
-24,978
| -17% | -$3.4M | 0.03% | 734 |
|
|
2020
Q1 | $14.6M | Sell |
149,744
-7,883
| -5% | -$901K | 0.03% | 609 |
|
|
2019
Q4 | $20.3M | Buy |
157,627
+96,586
| +158% | +$9.75M | 0.03% | 833 |
|
|
2019
Q3 | $4.6M | Sell |
61,041
-19,504
| -24% | -$2.3M | 0.01% | 1879 |
|
|
2019
Q2 | $12.2M | Sell |
80,545
-145,209
| -64% | -$17.6M | 0.02% | 1105 |
|
|
2019
Q1 | $26.9M | Buy |
225,754
+74,349
| +49% | +$9.56M | 0.04% | 626 |
|
|
2018
Q4 | $16.5M | Sell |
151,405
-473,335
| -76% | -$59.2M | 0.03% | 804 |
|
|
2018
Q3 | $101M | Sell |
624,740
-233,667
| -27% | -$31.9M | 0.12% | 187 |
|
|
2018
Q2 | $113M | Buy |
858,407
+507,588
| +145% | +$47.9M | 0.15% | 159 |
|
|
2018
Q1 | $26M | Sell |
350,819
-451,152
| -56% | -$30.1M | 0.03% | 745 |
|
|
2017
Q4 | $44.6M | Sell |
801,971
-380,297
| -32% | -$20.1M | 0.06% | 469 |
|
|
2017
Q3 | $53.6M | Sell |
1,182,268
-178,258
| -13% | -$7.12M | 0.08% | 320 |
|
|
2017
Q2 | $45.9M | Buy |
1,360,526
+1,226,065
| +912% | +$39.9M | 0.08% | 328 |
|
|
2017
Q1 | $3.98M | Sell |
134,461
-207,036
| -61% | -$6.41M | 0.01% | 1586 |
|
|
2016
Q4 | $9.37M | Sell |
341,497
-1,614,407
| -83% | -$64.8M | 0.02% | 962 |
|
|
2016
Q3 | $120M | Buy |
1,955,904
+1,612,454
| +469% | +$48.7M | 0.2% | 69 |
|
|
2016
Q2 | $6.55M | Buy |
343,450
+281,620
| +455% | +$5.22M | 0.02% | 1096 |
|
|
2016
Q1 | $1.21M | Sell |
61,830
-896,665
| -94% | -$15.7M | ﹤0.01% | 2083 |
|
|
2015
Q4 | $37M | Buy |
958,495
+413,024
| +76% | +$13.4M | 0.08% | 342 |
|
|
2015
Q3 | $17.5M | Buy |
545,471
+505,471
| +1,264% | +$17.2M | 0.03% | 630 |
|
|
2015
Q2 | $1.22M | Sell |
40,000
-40,000
| -50% | -$818K | ﹤0.01% | 2178 |
|
|
2015
Q1 | $1.06M | Sell |
80,000
-2,305
| -3% | -$30.7K | ﹤0.01% | 2280 |
|
|
2014
Q4 | $1.19M | Sell |
82,305
-5,299
| -6% | -$89.7K | ﹤0.01% | 2362 |
|
|
2014
Q3 | $1.85M | Sell |
87,604
-129,413
| -60% | -$2.92M | ﹤0.01% | 1926 |
|
|
2014
Q2 | $6.46M | Buy |
217,017
+196,357
| +950% | +$6.21M | 0.02% | 1043 |
|
|
2014
Q1 | $496K | Buy |
+20,660
| New | +$527K | ﹤0.01% | 2618 |
|
|
2013
Q4 | – | Sell |
-138,530
| Closed | -$4.12M | – | 3755 |
|
|
2013
Q3 | $6.54M | Buy |
138,530
+127,530
| +1,159% | +$4.91M | 0.02% | 958 |
|
|
2013
Q2 | $418K | Buy |
+11,000
| New | +$393K | ﹤0.01% | 2419 |
|
Other funds holding SRPT
EAM
Israel Englander's SRPT Position: Q2 2026 in Review
Israel Englander reduced its Sarepta Therapeutics (SRPT) stake by 2.3% in Q2 2026, selling an estimated $534K and leaving 1,193,468 shares worth $21.4M. The position accounts for 0.01% of the portfolio, ranked #1558.
Israel Englander first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $120M in Q3 2016. 320 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Israel Englander held 1,193,468 shares of Sarepta Therapeutics worth $21.4M as of Q2 2026.
- Israel Englander sold 28,214 Sarepta Therapeutics shares in Q2 2026, an estimated $534K.
- Sarepta Therapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1558 holding.
- Israel Englander first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Israel Englander's Sarepta Therapeutics position peaked at $120M in Q3 2016.
- 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.